<div class="summary"><p>Dompé farmaceutici Spa and FarmaMondo entered into an exclusive Managed Access Program distribution agreement appointing the FarmaMondo Group as the exclusive partner to make their innovative product Oxervate™ (Cenegermin) available for patients affected by Neurotrophic Keratitis (NK) in Russia and other CIS countries.</p></div><p>The agreement appoints FarmaMondo as the exclusive provider of access for those NK patients with unmet need through a Named Patient Managed Access Program. The possibility to access the therapy shall bring great hope for NK patients and their families in the region.</p><p>“We are pleased to be working with FarmaMondo to deliver this innovative treatment to patients with a serious unmet medical need. We believe expanding the distribution of Oxervate will dramatically improve the life of many now living with a highly debilitating disease,” said <strong>Eriona Gjinukaj</strong>, Chief Operating Officer of Dompé.</p>